The purpose of this assignment is for students to discuss how human genetic variations impact pharmacokinetics and pharmacodynamics of drugs and the application for use in the clinical setting. 

Activity Learning Outcomes 

Through this discussion, the student will demonstrate the ability to: 

1. Explain how pharmacogenomics is currently applied to clinical practice (CO 3,4,5). 
2. Discuss the limitations of pharmacogenomics testing (CO 3,4,5).  
3. Discuss ethical concerns related to pharmacogenomics testing and treatment (CO 3,4,5). 

Due Date: Wed. 11:59pm MT of Week 1 

The student must provide an initial response to the discussion topic by Wednesday, 11:59pm MT. Subsequent posts, including substantive responses to peer(s) and faculty questions must occur by Sunday, 11:59pm MT. A total of 3 substantive posts are required on 3 different days.  

A 10% late penalty will be imposed for initial discussions posted after the deadline on Wednesday 11:59pm MT, regardless of the number of days late. NOTHING will be accepted after 11:59pm MT on Sunday (i.e. student will receive an automatic 0).  

A 10% penalty will be imposed for not entering the minimum number of interactive dialogue posts (3) OR not posting on the minimum required number of days (3). NOTHING will be accepted after 11:59pm MT on Sunday (i.e. student will receive an automatic 0). 

Total Points Possible:  100 

Requirements: 

 In your initial post, respond to the following scenario (Hint: use the pharmgkb website to guide your responses): 

1. Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that the patient carries the HLA-B*5701 allele.  
   1. Describe what these results mean. 
   2. Should the nurse practitioner prescribe abacavir in this case? If not, state why. 
2. A patient is prescribed antiplatelet therapy (clopidogrel) following an acute myocardial infarction (MI). Six months later, the patient suffers another acute MI. The patient has been adherent to therapy and the nurse practitioner suspects that clopidrogel may have been ineffective. How might genetic testing have been beneficial in this case? 
3. Identify 2 limitations of pharmacogenomics testing. Explain. 
4. Identify 2 ethical concerns of using pharmacogenomics testing. Explain. 

* Textbooks, non-US journals, nursing journals not intended for advanced practice providers or websites intended for the general public are not considered scholarly.  

 Solution:

Describe what these results mean and if the nurse practitioner prescribe abacavir in this case? If not, state why

 If the test confirms that the patient carries the HLA-B*5701 allele, it implies that the patient carries a gene variant hence, an increased risk of hypersensitivity  (Mounzer et al., 2019). Abacavir hypersensitivity tends to occur within the first six weeks of taking abacavir and the patient is advised to stop taking this drug if he or she experiences symptoms such as rash, fever, gastrointestinal symptoms, and well as respiratory symptoms such as dyspnea.

Abacavir should not be prescribed to the above patient or any other drug that contain abacavir because the patient is at high risk of developing severe outcome or effects. An alternative drug that does not contain abacavir can be recommended to the patient…Please click the icon below to purchase full solution at $5